

pionic

Kickstarting chronic wound healing.

Bringing advanced wound care into patients home.





This document contains proprietary and sensitive information that is the property of Piomic Medical AG. It is furnished solely to assist in the evaluation of a potential business or investment relationship with Piomic Medical AG. Recipients of this memorandum understand that all of the information contained herein is confidential and agree that they will treat all such information in a confidential manner and will use such information only in the evaluation of the potential business or investment relationship. Recipients agree that they will not directly or indirectly disclose or distribute, or permit their agents to disclose or distribute, any such information without the prior consent of Piomic Medical AG.

This presentation may contain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities that involve a number of risks and uncertainties. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control.

By nature, these risks and uncertainties could cause actual results to differ materially from those indicated.

Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company's product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company's ability to manage its capital resource issues, competition, and the other factors. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

THE PROBLEM

Overaging population, rise of lifestyle diseases



Increasing
LIFE EXPECTANCY

Spreading
DIABETES

Requiring
INTENSIVE CARE

CHALLENGES FOR THE CURRENT SYSTEM

Trends towards homecare and self-management



INCREASING NUMBER OF PATIENTS

Rising life expectancy

EARLIER DISCHARGE

Faster transition to ambulatory care

HOMECARE

Growth of Independent care providers

PATIENT SELF-MANAGEMENT

Empowering patients for self-treatment

HARD-TO-HEAL WOUNDS

Chronic cutaneous ulcers




Over
50 Million
Patients


Every
30 Seconds
Amputation

CHRONIC WOUNDS

Stall in wound healing phase



COMS[®] STIMULATION
Promotion of wound healing processes



OUR SOLUTION

Allowing treatment of patients where they are, at home.

A simple and easy to use medical device that fits into your pocket.

To treat patients where they live.
At home.



Designed for Homecare

Lay-user validated



Intuitive

Single-button operated, minimal product training needed



Portable

Battery-powered, small, light weight and silent



Ease of use

Automated adjunctive treatment with minimal supervision



COMS® ONE THERAPY SYSTEM

Industrialized and ready to scale

Physical Stimulation

Medical Device Class IIa

Fully Industrialized

International Supply Chain

CE Marked

MDD Certificate until 2024

Homecare Compatible

Lay-user validated



HEALTH CARE ECOSYSTEM


Wound care needs



**REDUCING
HOSPITAL STAY**




**IMPROVING
HOME TREATMENT**



**ENABLING
PATIENT SELFMANAGEMENT**

FOLLOWING MARKET MEGATRENDS

And the patient journey




Timely transfer of patients has become a top priority, particularly in developed countries.

Therapies usable at home will be a key factor for revenue generation.

Wound management will flow seamlessly from hospital to out-patient settings.

ALLOWING POINT OF CARE CONVERSION

Enabling treatment in all major care settings



PLATFORM TECHNOLOGY


Diversification of indications



WOUND CARE



ORTHOPEDICS



SURGICAL

UPCOMING MILESTONES

Access to the worlds largest markets



Q2.2020

Q4.2020

Q1.2021

Q3.2023



CE MARK

START RANDOMIZED TRIAL

SOFT LAUNCH EU

HARD LAUNCH US

EXPERIENCED EXECUTIVE TEAM

Achieved milestones during major regulatory changes in European market

Business & Finance
MSc. Molecular Health
Science ETHZ

Christopher Hertz – CEO
Vice President of the Board



Clinical Research

Rejelle Williams
Clinical Trial Expert



Regulatory Affairs &
Quality Assurance

Adrian Meier
Process Optimizer



Operations &
Management

Industry & Innovation Expert
Martin Walti – COO



MSc. Mechanical
Engineering ETHZ
Research & Development

Dedicated Project Manager
Jari Kruth – CTO



Advisory Board



Dr. Jürg Traber
KOL Advanced Wound Care
Swiss Wound Care Association

Clinical Investigations



Dr. Ulf Benecke
KOL Advanced Wound Care
Swiss Wound Care Association

Clinical Investigations



Marc Walter
Co-Founder
Advisor

Clinical Research



Dr. Jürg Fröhlich
Chairman & Co-Founder
Serial Entrepreneur

Senior Scientist



Dominique Boulet
Board Member
VP Cardinal Health

Business Development



Bertrand Hughes
Board Member
Ex-Mölnlycke

Wound Care Specialist



Peter Hostettler
Board Member
Co-Founder Hocoma

Corporate Governance

Executive Board



Life shouldn't be defined by a medical condition.

Please contact us for more information

invest@piomic.com
+41 44 24 41 970



Piomic Medical AG
Reitergasse 6
CH-8004 Zürich
Switzerland

CHE-195.473.024

